Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Dec 27:2:1-6.
doi: 10.1016/j.ctro.2016.12.001. eCollection 2017 Feb.

Single nucleotide polymorphisms might influence chemotherapy induced nausea in women with breast cancer

Delmy Oliva  1   2 , Mats Nilsson  3 , Bengt-Åke Andersson  2   4 , Lena Sharp  5   6 , Freddi Lewin  1   2 , Nongnit Laytragoon-Lewin  2   4
Affiliations

Single nucleotide polymorphisms might influence chemotherapy induced nausea in women with breast cancer

Delmy Oliva et al. Clin Transl Radiat Oncol. .

Abstract

Background: Women receiving FEC (5 fluorouracil, epirubicin and cyclophosphamide) chemotherapy (CT) for breast cancer (BC) often experience side effects such as nausea and vomiting. Individual variations of side effects occur in patients despite similar cancer therapy. The purpose of this study was to investigate a possible genetic background as a predictor for individual variations in nausea induced by CT.

Methods: 114 women were included in the study. All women received adjuvant CT for BC. Self-reported nausea and vomiting was recorded in a structured diary over ten days following treatment. Blood samples were collected before the treatment and used for the detection of 48 single nucleotide polymorphisms (SNPs) in 43 genes. SNPs from each individual woman were analyzed for their relation to the patient-reported frequency and intensity of nausea and vomiting.

Results: Eighty-four percent (n = 96) of the women reported acute or delayed nausea or combined nausea and vomiting during the ten days following CT. Three out of the forty-eight SNPs in the following genes: FAS/CD95, RB1/LPAR6 and CCL2 were found to be associated with a risk of nausea.

Conclusion: SNPs in the FAS/CD95, RB1/LPAR6 and CCL2 genes were found to be associated with nausea among women treated with adjuvant FEC for BC. SNPs analysis is fast and cost effective and can be done prior to any cancer therapy. The association between individual SNPs and severe side effects from FEC may contribute to a more personalized care of patients with BC.

Keywords: Breast cancer; Chemotherapy; Nausea; Single nucleotide polymorphisms.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Inclusion process. FEC = 5 Fluorouracil, Epirubicin and Cyclophosphamide, SNP = single nucleotide polymorphisms.
Fig. 2
Fig. 2
(a) Reported total VAS-scores for nausea during the first 10 days after start of chemotherapy. (b) Self-reported day for most intense side effects during the first 10 days after start of chemotherapy.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Salonen P., Kellokumpu-Lehtinen P.L., Tarkka M.T., Koivisto A.M., Kaunonen M. Changes in quality of life in patients with breast cancer. J Clin Nurs. 2011;20(1–2):255–266. - PubMed
    1. Evangelista A.L., Santos E.M. Cluster of symptoms in women with breast cancer treated with curative intent. Support Care Cancer. 2012;20(7):1499–1506. - PubMed
    1. Liau C.T., Chu N.M., Deuson H.E., Lien J., Chen J.S. Incidence of chemotherapy-induced nausea and vomiting in Taiwan: physicians’ and nurses’ estimation vs. patients’ reported outcomes. Support Care Cancer. 2005;13(5):277–286. - PubMed
    1. Shih V., Wan H.S., Chan A. Clinical predictors of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adjuvant doxorubicin and cyclophosphamide. Ann Pharmacother. 2009;43(3):444–452. - PubMed
    1. Hesketh P.J. Jones and Bartlett Publishers; Canada: 2005. Management of nausea and vomiting in cancer and cancer treatment.